Abstract
Zika virus (ZIKV) is a mosquito-transmitted virus that has caused major outbreaks of disease around the world over the last few years. The infectious ZIKV consists of a structural protein outer shell surrounding a nucleocapsid. Virus-like particles (VLP) consist of the outer structural protein shell, but without the nucleocapsid, and are hence noninfectious. VLP, however, are structurally equivalent to the native virus and thus present a similar antigenic profile. These properties make them good candidates for vaccine development. ZIKV VLP can be generated on a laboratory scale by cloning the relevant structural proteins into a eukaryotic expression vector and transfecting the construct into mammalian cells. The secreted VLP can be harvested from the culture medium and purified by sucrose cushion ultracentrifugation. Validation of the VLP is achieved through western blotting and electron microscopy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Weaver SC, Barrett AD (2004) Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol 2(10):789–801
King AM, Adams MJ, Lefkowitz EJ, Carstens EB (2012) Virus taxonomy. In: IXth report of the International Committee on Taxonomy of Viruses, vol 9. Academic Press, San Diego, CA
Dick G, Kitchen S, Haddow A (1952) Zika virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hyg 46(5):509–520
Wikan N, Smith DR (2016) Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 16(7):E119–E126
Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, Sall AA, Musso D (2014) Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 20(6):1085–1086
Esposito DLA, de Moraes JB, Antonio Lopes da Fonseca B (2018) Current priorities in the Zika response. Immunology 153(4):435–442
Musso D, Gubler DJ (2016) Zika virus. Clin Microbiol Rev 29(3):487–524
Krauer F, Riesen M, Reveiz L, Oladapo OT, Martinez-Vega R, Porgo TV, Haefliger A, Broutet NJ, Low N, Group WHOZCW (2017) Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barre syndrome: systematic review. PLoS Med 14(1):e1002203
Barrett AD, Teuwen DE (2009) Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 21(3):308–313
Yun SI, Lee YM (2014) Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother 10(2):263–279
Halstead SB (2017) Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine 35(47):6355–6358
Krol E, Brzuska G, Szewczyk B (2019) Production and biomedical application of flavivirus-like particles. Trends Biotechnol 37:1202
Wikan N, Suputtamongkol Y, Yoksan S, Smith DR, Auewarakul P (2016) Immunological evidence of Zika virus transmission in Thailand. Asian Pac J Trop Med 9(2):136–139
Henchal EA, Gentry MK, McCown JM, Brandt WE (1982) Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31(4):830–836
Acknowledgments
This work was supported by Mahidol University, the Thailand Research Fund (BRG6080006) and the Newton Fund as administered by the National Science and Technology Development Agency (FDA-CO-2561-6820-TH).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kuadkitkan, A., Ramphan, S., Worawichawong, S., Sornjai, W., Wikan, N., Smith, D.R. (2021). Production of Zika Virus Virus-Like Particles. In: Pfeifer, B.A., Hill, A. (eds) Vaccine Delivery Technology. Methods in Molecular Biology, vol 2183. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0795-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0795-4_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0794-7
Online ISBN: 978-1-0716-0795-4
eBook Packages: Springer Protocols